Red Arrow Therapeutics, Co., Ltd. has been recognized as one of the ‘Top 10 Most Promising Biotech Startups from Asia – 2023’ by Asia Business Outlook magazine in their July issue! This prestigious recognition validates our commitment to innovation and transformative solutions in cancer immunotherapy. Join us in celebrating this milestone achievement!

https://www.asiabusinessoutlook.com/asia-startups/vendor/red-arrow-therapeutics-a-beacon-of-hope-for-cancer-patients-cid-1369.html

Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. will give a pitch presentation in front of Sr SF Investors @UC Berkeley at the PITCH GLOBAL event on August 20 (via Zoom).

More info: https://www.eventbrite.com/e/pitch-to-sr-sf-investors-via-zoominvestor-meetinguc-berkeley-tickets-358835174667

Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. gave a pitch presentation at the Pitch to CVC’s/VC’s’ angels +TDK&SK Group Thought Leadership that organized by the PITCH GLOBAL (www.pitchglobal.com).

Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. attended the Venture Summit West from July 19-20, 2022, in Silicon Valley, CA. We look forward to meeting with top innovators and investors there.

Prof. Horacio Cabral from Red Arrow Therapeutics, Co., Ltd. presented promising preclinical data of RA-001 (pH-sensitive polymeric micelles loading IL-12) at AACR Annual Meeting 2022. RA-001 demonstrated a potent anti-tumor immunity in multiple tumor models. Furthermore, RA-001 showed high efficacy as monotherapy and in combination with immune checkpoint inhibitors.

See Poster Presentation

Dr. Takuya Miyazaki, CEO from Red Arrow Therapeutics, Co. Ltd. joined a pitch event, namely, STEP to Biotech/Healthcare Startups powered by CIC/LINK-J. He performed two presentations to spread a company overview and to look for talented persons.

Red Arrow Therapeutics, Co. Ltd. will develop a pipeline by using AMED Seeds A grant. We aim to make proceedings on lead optimization by using this grant.

Red Arrow Therapeutics, Co. Ltd. closed their 1st seed round. They earned 0.8 M USD to develop their pipeline, IP and HR. They will look for additional fundings to earn 0.2-0.4 M USD by April.